Literature DB >> 23914798

Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors.

Xiaofei Liang1, Chul-Jin Lee2,3, Jinshi Zhao2, Eric J Toone1,2, Pei Zhou1,2,3.   

Abstract

The zinc-dependent deacetylase LpxC catalyzes the committed step of lipid A biosynthesis in Gram-negative bacteria and is a validated target for the development of novel antibiotics to combat multidrug-resistant Gram-negative infections. Many potent LpxC inhibitors contain an essential threonyl-hydroxamate headgroup for high-affinity interaction with LpxC. We report the synthesis, antibiotic activity, and structural and enzymatic characterization of novel LpxC inhibitors containing an additional aryl group in the threonyl-hydroxamate moiety, which expands the inhibitor-binding surface in LpxC. These compounds display enhanced potency against LpxC in enzymatic assays and superior antibiotic activity against Francisella novicida in cell culture. The comparison of the antibiotic activities of these compounds against a leaky Escherichia coli strain and the wild-type strain reveals the contribution of the formidable outer-membrane permeability barrier that reduces the compounds efficacy in cell culture and emphasizes the importance of maintaining a balanced hydrophobicity and hydrophilicity profile in developing effective LpxC-targeting antibiotics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23914798      PMCID: PMC3941642          DOI: 10.1021/jm4007774

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  Antibacterial agents that inhibit lipid A biosynthesis.

Authors:  H R Onishi; B A Pelak; L S Gerckens; L L Silver; F M Kahan; M H Chen; A A Patchett; S M Galloway; S A Hyland; M S Anderson; C R Raetz
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

2.  Refined solution structure of the LpxC-TU-514 complex and pKa analysis of an active site histidine: insights into the mechanism and inhibitor design.

Authors:  Brian E Coggins; Amanda L McClerren; Ling Jiang; Xuechen Li; Johannes Rudolph; Ole Hindsgaul; Christian R H Raetz; Pei Zhou
Journal:  Biochemistry       Date:  2005-02-01       Impact factor: 3.162

3.  Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design.

Authors:  Chul-Jin Lee; Xiaofei Liang; Xin Chen; Daina Zeng; Sang Hoon Joo; Hak Suk Chung; Adam W Barb; Shauna M Swanson; Robert A Nicholas; Yaoxian Li; Eric J Toone; Christian R H Raetz; Pei Zhou
Journal:  Chem Biol       Date:  2010-12-16

4.  Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site.

Authors:  J E Jackman; C R Raetz; C A Fierke
Journal:  Biochemistry       Date:  2001-01-16       Impact factor: 3.162

5.  Stereoselective synthesis of four stereoisomers of beta-methoxytyrosine, a component of callipeltin A.

Authors:  Darren B Hansen; Xiaobo Wan; Patrick J Carroll; Madeleine M Joullié
Journal:  J Org Chem       Date:  2005-04-15       Impact factor: 4.354

Review 6.  Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis.

Authors:  Adam W Barb; Pei Zhou
Journal:  Curr Pharm Biotechnol       Date:  2008-02       Impact factor: 2.837

7.  Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding.

Authors:  Adam W Barb; Ling Jiang; Christian R H Raetz; Pei Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-19       Impact factor: 11.205

8.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Authors:  Bhupinder S Mann; John R Johnson; Martin H Cohen; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2007-10

Review 9.  Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria.

Authors:  Louis B Rice
Journal:  Cleve Clin J Med       Date:  2007-08       Impact factor: 2.321

10.  Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Diabetes Metab Syndr Obes       Date:  2013-01-04       Impact factor: 3.168

View more
  11 in total

1.  Structural basis of the promiscuous inhibitor susceptibility of Escherichia coli LpxC.

Authors:  Chul-Jin Lee; Xiaofei Liang; Ramesh Gopalaswamy; Javaria Najeeb; Eugene D Ark; Eric J Toone; Pei Zhou
Journal:  ACS Chem Biol       Date:  2013-10-31       Impact factor: 5.100

2.  LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents.

Authors:  Haruaki Kurasaki; Kosuke Tsuda; Mariko Shinoyama; Noriko Takaya; Yuko Yamaguchi; Ryuta Kishii; Kazuhiko Iwase; Naoki Ando; Masahiro Nomura; Yasushi Kohno
Journal:  ACS Med Chem Lett       Date:  2016-04-05       Impact factor: 4.345

3.  Synthesis, Structure, and SAR of Tetrahydropyran-Based LpxC Inhibitors.

Authors:  Kerry E Murphy-Benenato; Nelson Olivier; Allison Choy; Philip L Ross; Matthew D Miller; Jason Thresher; Ning Gao; Michael R Hale
Journal:  ACS Med Chem Lett       Date:  2014-09-23       Impact factor: 4.345

Review 4.  Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.

Authors:  Alice L Erwin
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

5.  Development of a Potent and Selective HDAC8 Inhibitor.

Authors:  Oscar J Ingham; Ronald M Paranal; William B Smith; Randolph A Escobar; Han Yueh; Tracy Snyder; John A Porco; James E Bradner; Aaron B Beeler
Journal:  ACS Med Chem Lett       Date:  2016-09-01       Impact factor: 4.345

6.  Structural basis of the UDP-diacylglucosamine pyrophosphohydrolase LpxH inhibition by sulfonyl piperazine antibiotics.

Authors:  Jae Cho; Minhee Lee; C Skyler Cochrane; Caroline G Webster; Benjamin A Fenton; Jinshi Zhao; Jiyong Hong; Pei Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-10       Impact factor: 11.205

7.  Synthesis, antibacterial and anticancer activity, and docking study of aminoguanidines containing an alkynyl moiety.

Authors:  Xianqing Deng; Mingxia Song
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 8.  Lipid A as a Drug Target and Therapeutic Molecule.

Authors:  Sang Hoon Joo
Journal:  Biomol Ther (Seoul)       Date:  2015-11-01       Impact factor: 4.634

9.  Crystal structure of lipid A disaccharide synthase LpxB from Escherichia coli.

Authors:  Thomas E Bohl; Ke Shi; John K Lee; Hideki Aihara
Journal:  Nat Commun       Date:  2018-01-25       Impact factor: 14.919

10.  Interplay of Klebsiella pneumoniae fabZ and lpxC Mutations Leads to LpxC Inhibitor-Dependent Growth Resulting from Loss of Membrane Homeostasis.

Authors:  Mina Mostafavi; Lisha Wang; Lili Xie; Kenneth T Takeoka; Daryl L Richie; Fergal Casey; Alexey Ruzin; William S Sawyer; Christopher M Rath; Jun-Rong Wei; Charles R Dean
Journal:  mSphere       Date:  2018-10-31       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.